XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 29.81

-4.2%

Dec 5 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Robert K. who wrote (13725)	5/30/2000 11:43:00 PM
From: aknahow	Read Replies (1) of 17367

Robert, how common are fungal and protozoal infections of the eye? Just interested, not a big issue. I was not aware that any protozoan infection was a big deal in the U.S. On sales IMO it is a matter of how fast AGN will want to canabalize its' existing products. Think it will be faster than I estimated since capturing more of the entire market can best be done by selling a new novel product with demonstrated advantages. The existing sales of AGN provided earlier, include non U.S. sales, but as you point out if resistance is a factor then they might be in a better position to capture new sales with a better product.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next